Literature DB >> 10399364

Transgenic over-expression of a motor protein at high levels results in severe cardiac pathology.

J James1, H Osinska, T E Hewett, T Kimball, R Klevitsky, S Witt, D G Hall, J Gulick, J Robbins.   

Abstract

Transgenesis has become a useful tool in effecting a complete or partial remodeling of the cardiac contractile apparatus. Although gene dosage effects were initially a concern, recent data showed that the heart is able to accommodate varying levels of transgenic over-expression without detectable ill effects. The present study was designed to test the limits of the transgenic paradigm in terms of the production of a cardiac phenotype due simply to the over-expression of a contractile protein. To this end, eight lines of mice which express an isoform of the essential myosin light chain 1 that is normally found in the adult ventricle (ELC1v) were generated. Overt phenotype was correlated both with the level of expression/protein replacement and copy number of the transgene. Two of the lines showed essentially complete replacement of the atrial isoform (ELC1a) with ELC1v. However, the phenotypes of the two lines differed dramatically. The line with the lower copy number (37 copies), and moderate over-expression (16 fold) showed no overt pathology while a line with very high copy number (94 copies) and extremely high levels of over-expression (27-50 fold) developed a significant atrial hypertrophy, dilation and cardiomyopathy. These data indicate that very high expression levels of a contractile protein can cause a cardiac pathology that is unrelated to its degree of replacement in the sarcomere and the unique role(s) it may assume in motor protein function.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10399364     DOI: 10.1023/a:1008894507995

Source DB:  PubMed          Journal:  Transgenic Res        ISSN: 0962-8819            Impact factor:   2.788


  26 in total

1.  Cardiac myosin heavy chain mRNA expression and myocardial function in the mouse heart.

Authors:  W A Ng; I L Grupp; A Subramaniam; J Robbins
Journal:  Circ Res       Date:  1991-06       Impact factor: 17.367

2.  Manipulating myosin light chain 2 isoforms in vivo: a transgenic approach to understanding contractile protein diversity.

Authors:  R Kelly; M Buckingham
Journal:  Circ Res       Date:  1997-05       Impact factor: 17.367

3.  Ablation of the murine alpha myosin heavy chain gene leads to dosage effects and functional deficits in the heart.

Authors:  W K Jones; I L Grupp; T Doetschman; G Grupp; H Osinska; T E Hewett; G Boivin; J Gulick; W A Ng; J Robbins
Journal:  J Clin Invest       Date:  1996-10-15       Impact factor: 14.808

4.  Remodeling the mammalian heart using transgenesis.

Authors:  J Palermo; J Gulick; W Ng; I L Grupp; G Grupp; J Robbins
Journal:  Cell Mol Biol Res       Date:  1995

5.  Function of the N terminus of the myosin essential light chain of vertebrate striated muscle.

Authors:  H L Sweeney
Journal:  Biophys J       Date:  1995-04       Impact factor: 4.033

Review 6.  Molecular genetic analysis of muscle development, structure, and function in Drosophila.

Authors:  S I Bernstein; P T O'Donnell; R M Cripps
Journal:  Int Rev Cytol       Date:  1993

7.  Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice.

Authors:  J J Hunter; N Tanaka; H A Rockman; J Ross; K R Chien
Journal:  J Biol Chem       Date:  1995-09-29       Impact factor: 5.157

8.  Echocardiographic assessment of left ventricular mass and systolic function in mice.

Authors:  J M Gardin; F M Siri; R N Kitsis; J G Edwards; L A Leinwand
Journal:  Circ Res       Date:  1995-05       Impact factor: 17.367

9.  Length dependence of Ca2+ sensitivity of tension in mouse cardiac myocytes expressing skeletal troponin C.

Authors:  K S McDonald; L J Field; M S Parmacek; M Soonpaa; J M Leiden; R L Moss
Journal:  J Physiol       Date:  1995-02-15       Impact factor: 5.182

Review 10.  Strategies for studying cardiovascular phenotypes in genetically manipulated mice.

Authors:  K D Becker; K R Gottshall; K R Chien
Journal:  Hypertension       Date:  1996-03       Impact factor: 10.190

View more
  15 in total

Review 1.  Meeting Koch's postulates for calcium signaling in cardiac hypertrophy.

Authors:  K R Chien
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

2.  Cardiac expression of Gal4 causes cardiomyopathy in a dose-dependent manner.

Authors:  Petra E M H Habets; Danielle E W Clout; Ronald H Lekanne Deprez; Marian A van Roon; Antoon F M Moorman; Vincent M Christoffels
Journal:  J Muscle Res Cell Motil       Date:  2003       Impact factor: 2.698

3.  Characterization of stable fluorescent transgenic marine medaka (Oryzias dancena) lines carrying red fluorescent protein gene driven by myosin light chain 2 promoter.

Authors:  Young Sun Cho; Sang Yoon Lee; Dong Soo Kim; Yoon Kwon Nam
Journal:  Transgenic Res       Date:  2012-11-28       Impact factor: 2.788

4.  Altered focal adhesion regulation correlates with cardiomyopathy in mice expressing constitutively active rac1.

Authors:  M A Sussman; S Welch; A Walker; R Klevitsky; T E Hewett; R L Price; E Schaefer; K Yager
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

5.  Forced expression of alpha-myosin heavy chain in the rabbit ventricle results in cardioprotection under cardiomyopathic conditions.

Authors:  Jeanne James; Lisa Martin; Maike Krenz; Carmen Quatman; Fred Jones; Raisa Klevitsky; James Gulick; Jeffrey Robbins
Journal:  Circulation       Date:  2005-05-02       Impact factor: 29.690

6.  Healing a Heart Through Genetic Intervention.

Authors:  Jeanne James; Jeffrey Robbins
Journal:  Circ Res       Date:  2016-03-18       Impact factor: 17.367

Review 7.  Lost in transgenesis: a user's guide for genetically manipulating the mouse in cardiac research.

Authors:  Jennifer Davis; Marjorie Maillet; Joseph M Miano; Jeffery D Molkentin
Journal:  Circ Res       Date:  2012-08-31       Impact factor: 17.367

Review 8.  Challenges and opportunities in dystrophin-deficient cardiomyopathy gene therapy.

Authors:  Dongsheng Duan
Journal:  Hum Mol Genet       Date:  2006-10-15       Impact factor: 6.150

9.  Functional ability of cytoskeletal β-actin regulator to drive constitutive and ubiquitous expression of a fluorescent reporter throughout the life cycle of transgenic marine medaka Oryzias dancena.

Authors:  Young Sun Cho; Sang Yoon Lee; Youn Kyoung Kim; Dong Soo Kim; Yoon Kwon Nam
Journal:  Transgenic Res       Date:  2011-03-25       Impact factor: 2.788

Review 10.  Genetic approaches for changing the heart and dissecting complex syndromes.

Authors:  Michael-Alice Moga; Tomoki Nakamura; Jeffrey Robbins
Journal:  J Mol Cell Cardiol       Date:  2008-06-14       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.